Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

NCT07178912 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Phase II Clinical Trial
Blinatumomab
Olverembatinib
Lymphoblastic Leukemia
Philadelphia Chromosome Positive

Interventions

DRUG: Blinatumomab
DRUG: olverembatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]